Ask Question
Sign Guest book
 
About Lymphoma | Advocacy & Art | CAM & Life Style | Clinical trials | Docs & Centers | Guidelines at Diagnosis | How  to Help | Side Effects | Support | Symptoms  | Tests | Treatments | Types of Lymphoma


Experts

Clinical Trials of Interest - First Line Primary

  

Treatments or Clinical Trials > Clinical Trials of Interest

Clinical Circumstance:  First Primary Therapy for Previously Untreated

Last update: 11/20/2009 

 First Line Low Toxic  | First Primary Therapy | Relapsed / refractory | Addressing other unmet needs
Subtypes: 
DLBCL / aggressive | Follicular / Low grade | Mantle Cell | T-cell | CLL/SLL

Also see: First line Therapies for Lymphoma in ClinicalTrials.gov

Untreated Diffuse Large B-Cell Lymphoma / aggressive b-cell lymphoma

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert. 

R-CHOP + Azacytidine  
See for Azacytidine 

 Condition: Previously untreated Diffuse Large B-cell Lymphoma 
R-CHOP Versus. Dose-Adjusted EPOCH-R With Molecular Profiling 

Condition: Previously untreated Diffuse Large B-cell Lymphoma 
Lenalidomide (Revlimid), plus CHOP-R  
See for Lenalidomide

Condition: Previously untreated Diffuse Large B-cell Lymphoma 
Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy

Condition: Previously untreated Diffuse Large B-cell Lymphoma
Rituxan + CHOP versus Dose-Adjusted EPOCH-Rituxan with molecular Profiling
  
Condition: Previously untreated Diffuse Large B-cell Lymphoma

Bexxar with CHOP-Rituxan (SWOG-0433)

Condition: Patients ≥ Age 60 With Advanced Stage Diffuse Large B-Cell NHL
Vorinostat (Zolinza* ), Rituxan, and Combination Chemotherapy  
See for Zolinza 

Condition: Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy  
See for Everolimus (RAD001)

Condition: high risk Diffuse Large B-Cell Lymphoma in complete response
CHOP + Rituxan + Bortezomib (Velcade)
See for Velcade

Condition: Previously untreated Diffuse Large B-cell Lymphoma or Mantle Cell lymphoma

 

Untreated Follicular Lymphoma or Low Grade Lymphoma

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert.  

Early stage:
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma 
 
Condition: Previously untreated early stage follicular lymphoma 
New combinations:
Rituxan, Cyclophosphamide, Velcade, and Prednisone in Treating Patients With Stage III or Stage IV Follicular Lymphoma or Marginal Zone Lymphoma 

Condition: Previously untreated follicular and Marginal Zone lymphomas
Bendamustine, Mitoxantrone, and Rituximab (BMR) 

Condition: Previously untreated high risk follicular lymphoma 
(as defined by a FLIPI score >/= 3.)
Lenalidomide (Revlimid), Rituxan, and Combination Chemotherapy

Condition: Previously untreated follicular lymphoma, stage II-IV 
Radioimmunotherapy-based:
Bexxar, Rituxan, and Combination Chemotherapy 

Condition: Previously untreated stage III or IV follicular lymphoma 
Zevalin Following R-CVP versus Observation

Condition: Previously untreated high risk follicular lymphoma as defined by a follicular lymphoma international prognostic index (FLIPI) of 3, 4, or 5 assessed within 3 months prior to randomization." 
CHOP with Rituxan versus CHOP followed by Bexxar
 
Conditions: Previously untreated grade 1 - grade 3 follicular lymphoma 

 

Untreated Mantle Cell lymphoma

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert. 

Bexxar followed by six cycles of CHOP
 
Condition: Previously untreated Mantle Cell Lymphoma
Vaccine with Interleukin-2 After Combination Chemotherapy
  
Condition: Previously treated, or untreated, Mantle Cell Lymphoma

Untreated T-cell lymphoma (under construction)

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert. 

Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP 

Conditions: Peripheral T Cell Lymphoma, Unspecified;   Angioimmunoblastic Lymphadenopathy;   AIL Type Lymphoma;   Anaplastic Large Cell Lymphoma, ALK Negative;   Extranodal NK/T-Cell Lymphoma
Alemtuzumab and CHOP in T-cell Lymphoma 

Conditions: Lymphoma, T-Cell, Peripheral
CHOP and ONTAK
 
Conditions: Treatment naïve, except for prior radiation or a single cycle of CHOP
T-Cell lymphoma, REAL classification 

 

Untreated Hodgkins lymphoma (under construction)

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert.   

KGEL Vaccine After Initial Chemotherapy
Condition: Previously untreated Hodgkin's Disease

 

Untreated CLL/SLL (under construction)

Patients and caregivers: Feel free to contact the investigators directly, but do ask that he or she communicate with your physician to discuss how appropriate the study is for your circumstance. Ideally, consult also with an independent lymphoma expert. 

 

Lenalidomide as Initial Treatment,  Age 65 and Older
Fludarabine and Rituxan Followed  by Bexxar 
 
Conditions:  Previously untreated:
   Chronic Lymphocytic Leukemia (CLL) ; 
   Small Lymphocytic Lymphoma (SLL)
 
Disclaimer:  The information presented on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.